Pathologists tend to reclassify prior nonmalignant diagnoses

August 17, 2012
Pathologists tend to reclassify prior nonmalignant diagnoses
For dermatopathologists there is a trend toward reclassification of prior nonmalignant diagnoses of severely atypical dysplastic nevi as malignant, according to a study published in the September issue of the Journal of the American Academy of Dermatology.

(HealthDay) -- For dermatopathologists there is a trend toward reclassification of prior nonmalignant diagnoses of severely atypical dysplastic nevi as malignant, according to a study published in the September issue of the Journal of the American Academy of Dermatology.

Jason E. Frangos, M.D., from Harvard Medical School in Boston, and colleagues had a group of nine dermatopathologists review retrieved files and reevaluate 29 cases of dysplastic nevi with severe atypia and 11 cases of thin radial growth-phase melanoma, originally diagnosed in 1988 through 1990.

The researchers found the mean number of melanoma diagnoses in the revaluation to be 18, an increase from the 11 original diagnoses of melanoma. In all 11 cases, a majority agreed with the original melanoma diagnosis. In four of the 29 cases originally reported as dysplastic nevus with severe atypia, a majority of current raters diagnosed melanoma. Interrater agreement over time was excellent for cases originally diagnosed as melanoma (kappa, 0.88), and fair for cases originally diagnosed as severely atypical dysplastic nevus (kappa, 0.47).

"The results of this study provide support for the hypothesis that dermatopathologists are more likely to diagnose thin superficial spreading in biopsy specimens that were reported as dysplastic nevi with severe atypia in the past, e.g., some 20 years ago," the authors write.

Explore further: Risk of second primary melanoma up in pediatric patients

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Risk of second primary melanoma up in pediatric patients

June 28, 2012
(HealthDay) -- Pediatric patients diagnosed with an invasive cutaneous melanoma have nearly double the relative risk of developing a subsequent primary melanoma, compared with adults, according to a study published online ...

Accuracy of melanoma detection up in specialized clinics

June 21, 2012
(HealthDay) -- From 1998 to 2007, the accuracy of melanoma detection improved in specialized but not non-specialized clinical settings, according to research published in the July issue of the Journal of the American Academy ...

Recommended for you

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.